General Prognostics

General Prognostics (GPx) is a Boston-based digital health company revolutionizing remote chronic disease management through the world's first bloodless blood tests. The company's AI platform calibrates clinically validated digital biomarkers — captured from consumer wearables — against traditional blood biomarker datasets, enabling continuous, non-invasive monitoring of critical blood markers without any blood draw. Its flagship product, CardioID, delivers real-time patient status changes to clinicians, allowing timely intervention for patients with chronic conditions such as heart disease. GPx is headquartered in Boston, Massachusetts, and is backed by NEC and other investors focused on digital health innovation.